235 related articles for article (PubMed ID: 16842232)
1. From proteins to nucleic acid-based drugs: the role of biotech in anti-VEGF therapy.
Gatto B; Cavalli M
Anticancer Agents Med Chem; 2006 Jul; 6(4):287-301. PubMed ID: 16842232
[TBL] [Abstract][Full Text] [Related]
2. Vascular endothelial growth factor (VEGF) as a target of bevacizumab in cancer: from the biology to the clinic.
Ranieri G; Patruno R; Ruggieri E; Montemurro S; Valerio P; Ribatti D
Curr Med Chem; 2006; 13(16):1845-57. PubMed ID: 16842197
[TBL] [Abstract][Full Text] [Related]
3. Treating age-related macular degeneration - interaction of VEGF-antagonists with their target.
Klettner A; Roider J
Mini Rev Med Chem; 2009 Aug; 9(9):1127-35. PubMed ID: 19689408
[TBL] [Abstract][Full Text] [Related]
4. Promising new treatments for neovascular age-related macular degeneration.
Michels S; Schmidt-Erfurth U; Rosenfeld PJ
Expert Opin Investig Drugs; 2006 Jul; 15(7):779-93. PubMed ID: 16787141
[TBL] [Abstract][Full Text] [Related]
5. Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy.
Ferrara N; Hillan KJ; Novotny W
Biochem Biophys Res Commun; 2005 Jul; 333(2):328-35. PubMed ID: 15961063
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic anti-VEGF antibodies.
Lien S; Lowman HB
Handb Exp Pharmacol; 2008; (181):131-50. PubMed ID: 18071944
[TBL] [Abstract][Full Text] [Related]
7. [VEGF and its receptors as therapeutic target in cancer therapy].
Gisterek I; Kornafel J
Przegl Lek; 2006; 63(3):155-7. PubMed ID: 16967703
[TBL] [Abstract][Full Text] [Related]
8. Targeting vascular endothelial growth factor: a promising strategy for treating age-related macular degeneration.
Waisbourd M; Loewenstein A; Goldstein M; Leibovitch I
Drugs Aging; 2007; 24(8):643-62. PubMed ID: 17702534
[TBL] [Abstract][Full Text] [Related]
9. Tumor angiogenesis and accessibility: role of vascular endothelial growth factor.
Jain RK
Semin Oncol; 2002 Dec; 29(6 Suppl 16):3-9. PubMed ID: 12516032
[TBL] [Abstract][Full Text] [Related]
10. Role of vascular endothelial growth factor in physiologic and pathologic angiogenesis: therapeutic implications.
Ferrara N
Semin Oncol; 2002 Dec; 29(6 Suppl 16):10-4. PubMed ID: 12516033
[TBL] [Abstract][Full Text] [Related]
11. Tumor angiogenesis and anti-angiogenic therapies.
Shahneh FZ; Baradaran B; Zamani F; Aghebati-Maleki L
Hum Antibodies; 2013; 22(1-2):15-9. PubMed ID: 24284305
[TBL] [Abstract][Full Text] [Related]
12. The vascular endothelial growth factors and receptors family: Up to now the only target for anti-angiogenesis therapy.
Tarallo V; De Falco S
Int J Biochem Cell Biol; 2015 Jul; 64():185-9. PubMed ID: 25936669
[TBL] [Abstract][Full Text] [Related]
13. [Treatment of neovascular age-related macular degeneration with antiangiogenic drugs].
Rodrigues EB; Rossi EE; Grumann Junior A; Meyer CH; Ho AC
Arq Bras Oftalmol; 2006; 69(5):756-65. PubMed ID: 17187150
[TBL] [Abstract][Full Text] [Related]
14. [VEGF inhibitors in ophthalmology].
Thys J; Dupont G; Rakic JM
Rev Med Liege; 2009; 64(5-6):323-6. PubMed ID: 19642468
[TBL] [Abstract][Full Text] [Related]
15. Systemic and ocular safety of intravitreal anti-VEGF therapies for ocular neovascular disease.
Tolentino M
Surv Ophthalmol; 2011; 56(2):95-113. PubMed ID: 21335144
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of tumor angiogenesis by antibodies, synthetic small molecules and natural products.
Wahl O; Oswald M; Tretzel L; Herres E; Arend J; Efferth T
Curr Med Chem; 2011; 18(21):3136-55. PubMed ID: 21671856
[TBL] [Abstract][Full Text] [Related]
17. Anti-Angiogenic Drugs, Vascular Toxicity and Thromboembolism in Solid Cancer.
Riondino S; Del Monte G; Fratangeli F; Guadagni F; Roselli M; Ferroni P
Cardiovasc Hematol Agents Med Chem; 2017; 15(1):3-16. PubMed ID: 28137223
[TBL] [Abstract][Full Text] [Related]
18. [Anti-angiogenic drugs].
Sato Y
Nihon Rinsho; 2010 Jun; 68(6):1054-8. PubMed ID: 20535955
[TBL] [Abstract][Full Text] [Related]
19. Monoclonal antibodies targeting vascular endothelial growth factor: current status and future challenges in cancer therapy.
Hsu JY; Wakelee HA
BioDrugs; 2009; 23(5):289-304. PubMed ID: 19754219
[TBL] [Abstract][Full Text] [Related]
20. Comparative effects of bevacizumab, ranibizumab and pegaptanib at intravitreal dose range on endothelial cells.
Carneiro A; Falcão M; Pirraco A; Milheiro-Oliveira P; Falcão-Reis F; Soares R
Exp Eye Res; 2009 Mar; 88(3):522-7. PubMed ID: 19135441
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
